2023
Dzhumashev D, Anton-Joseph S, Morel VJ, Timpanaro A, Bordon G, Piccand C, Aleandri S, Luciani P, Rössler J, Bernasconi M. Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells. Eur J Pharm Biopharm. 2023 Nov 27;. doi: 10.1016/j.ejpb.2023.11.020. [Epub ahead of print] PubMed PMID: 38029941.
Timpanaro A, Piccand C, Dzhumashev D, Anton-Joseph S, Robbi A, Moser J, Rössler J, Bernasconi M. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models. J Exp Clin Cancer Res. 2023 Nov 4;42(1):293. doi: 10.1186/s13046-023-02838-3. PubMed PMID: 37924157; PubMed Central PMCID: PMC10625270.
Timpanaro A, Piccand C, Uldry AC, Bode PK, Dzhumashev D, Sala R, Heller M, Rössler J, Bernasconi M. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma. Int J Mol Sci. 2023 Jan 30;24(3). doi: 10.3390/ijms24032601. PubMed PMID: 36768928; PubMed Central PMCID: PMC9917031.
2022
Dzhumashev D, Timpanaro A, Ali S, De Micheli AJ, Mamchaoui K, Cascone I, Rössler J, Bernasconi M. Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma. Cancers (Basel). 2022 Oct 14;14(20). doi: 10.3390/cancers14205048. PubMed PMID: 36291832; PubMed Central PMCID: PMC9600270.
2021
Sidorov S, Fux L, Steiner K, Bounlom S, Traxel S, Azzi T, Berisha A, Berger C, Bernasconi M, Niggli FK, Perner Y, Pather S, Kempf W, Nadal D, Bürgler S. CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes. Cancer Immunol Immunother. 2021 Oct 19. doi: 10.1007/s00262-021-03057-5. Epub ahead of print. PMID: 34668039.
2020
Alijaj N, Moutel S, Gouveia ZL, Gray M, Roveri M, Dzhumashev D, Weber F, Meier G, Luciani P, Rössler JK, Schäfer BW, Perez F, Bernasconi M. Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. Cancers (Basel). 2020 Nov 10;12(11):3313. doi: 10.3390/cancers12113313. PMID: 33182650; PMCID: PMC7696840.
Daurat M , Nguyen C , Dominguez Gil S , Sol V , Chaleix V , Charnay C , Raehm L , El Cheikh K , Morère A , Bernasconi M , Timpanaro A , Garcia M , Cunin F , Roessler J , Durand JO , Gary-Bobo M . The mannose 6-phosphate receptor targeted with porphyrin-based periodic mesoporous organosilica nanoparticles for rhabdomyosarcoma theranostics. Biomater Sci. 2020 Jul 7;8(13):3678-3684. doi: 10.1039/d0bm00586j. Epub 2020 May 29. PMID: 32469353.
2019
Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T, Ohara K, Hirata-Nozaki Y, Harabuchi S, Hayashi R, Ohkuri T, Bernasconi M, Nadal D, Kobayashi H, Harabuchi Y. Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. Lab Invest. 2019 May;99(5):612-624. doi: 10.1038/s41374-018-0182-9. Epub 2019 Jan 21. PMID: 30664711.
NCBi my biblography https://www.ncbi.nlm.nih.gov/myncbi/michele.bernasconi.1/bibliography/public/
